Investing.comDoubao · 实盘不做把握 7/10不做原因:证据不足
北京时间·🕒 发布 20:04:33·⟳ 抓取 20:05:35 +1m02s·⚡ 决策 10-12 20:07:17 +1m42s·15.0 天前
Stoke Therapeutics 在 AAO 2026 公布 STK-002 治疗 ADOA 的 OSPREY I 期前两队列给药完成进展，尚无疗效读出
本次披露未提供任何疗效/安全性阳性读出：OSPREY 仅完成前两个剂量队列给药，真正用于验证视力功能的第三、四队列初步数据要到 2027 上半年；FALCON 只是自然史氧化应激机制结果。对临床前商业化生物科技公司，这属于按既有时间表推进的进展更新而非改变资产状态的催化，不构成可交易的预期差。
📄 原文Investing.com↗ 原文
Stoke Therapeutics presents data on ADOA treatment STK-002
By Investing.com Advertisement Advertisement Stoke Therapeutics presents data on ADOA treatment STK-002 Company News Pu…
不做 Stoke Therapeutics Inc.（STOK.US）
无疗效/安全性阳性读出，仅 I 期前两队列给药完成与自然史机制数据，属按时间表的进展更新，不构成资产状态迁移或预期差；关键催化（第三/四队列数据）在 2027H1，当前无短线正 edge。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Stoke 的 STK-002 仍处 I 期，关键疗效数据未出（2027H1），AAO 披露的是给药进度和自然史机制数据，没有阳性 topline 或状态跃迁，缺乏短线 edge，回避。
🔎 新鲜度:最早出现 2026-10-12 · 扩散 low · price-in 风险 low ↗
关键理由
- 事件未把资产从 I 期推进到阳性读出等新状态，第三/四队列疗效数据 2027H1 才公布，当前无可定价的增量信息
主要风险
- 若会议口头交流或公司另有未被通稿覆盖的超预期数据，盘前可能跳空（无法证实，属上行尾部风险而非本决策依据）
反向证据
- 做多前查反向 · 来源 web · 影响 none
尝试联网核实是否存在通稿外超预期数据，但搜索服务握手超时，未取得反证；正文自身已确认关键疗效数据未出。
检索:Stoke Therapeutics STK-002 OSPREY AAO 2026 efficacy safety readout
先例如何影响了这次决策
对本次决策的影响:支持回避：不 ENTER、不设价，等待 2027H1 疗效读出这一真正状态迁移节点再评估。
方向:无可用对齐先例：本次不是阳性/阴性 topline 读出，而是 I 期进度+自然史机制数据，与可定价临床读出不同机制，不应套用临床读出类涨幅。
涨幅量级:不足以校准幅度；事件本身无疗效数字，定 tp/sl 无意义。
形态:进度型会议海报/通稿通常难以形成持续驱动，真正催化在 2027H1 第三/四队列数据。
工具执行结果 · 成功 2 · 降级 0 · 失败 1 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 11 ms
{"result": "search_processed_events:agent query=`stok osprey falcon data presentation american academy ophthalmology | stoke therapeutics opa1 antisense optic atrophy cohort dosing | stoke therapeutics stk-002 adoa osprey phase 1`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agen - fetch_decision_experience 成功 stock_tools_inprocess · 2 ms
{ - web_search 失败 doubao_search · 5,082 ms
ConnectTimeout: web_search 失败:豆包搜索 ConnectTimeout: _ssl.c:993: The handshake operation timed out
原文全文
展开原文 · 7,658 字
Stoke Therapeutics presents data on ADOA treatment STK-002 By Investing.com
Advertisement
Advertisement
Stoke Therapeutics presents data on ADOA treatment STK-002
Company News
Published
Oct 12, 2026, 08:04 AM
Stoke Therapeutics presents data on ADOA treatment STK-002
View all comments (0)
0
Stoke Therapeutics presents data on ADOA treatment STK-002
View all comments (0)
0
© Reuters
In this article:
STOK
+
3.30%
BEDFORD, Mass. -
Stoke Therapeutics
Inc. (
NASDAQ:STOK
) presented data on its experimental treatment STK-002 for Autosomal Dominant Optic Atrophy at the American Academy of Ophthalmology 2026 Annual Meeting, which concluded Sunday in New Orleans.
The company announced that dosing has been completed in the first two cohorts of its Phase 1 OSPREY study, with the third cohort expected to complete by the end of 2026. Initial safety and efficacy data from cohorts three and four are anticipated in the first half of 2027, according to a press release statement.
ADOA is the most common inherited optic nerve disorder, affecting approximately one in 25,000 people globally. The condition is primarily caused by variants in the OPA1 gene, resulting in insufficient levels of OPA1 protein and leading to progressive vision loss. There are currently no approved treatments for the disease.
STK-002 is an antisense oligonucleotide designed to increase functional OPA1 protein by targeting the healthy copy of the OPA1 gene. An estimated 65% to 90% of ADOA cases are caused by variants in the OPA1 gene.
The OSPREY study is enrolling children and adults ages 6 to 55 with confirmed ADOA diagnoses and disease-causing OPA1 gene variants. The study’s primary objectives are to assess safety and tolerability of single ascending doses of STK-002, with secondary objectives evaluating changes in visual function and quality of life.
"Dose cohorts three and four are designed to show measurable effects on visual function," said Barry Ticho, Chief Medical Officer of Stoke Therapeutics.
The company also presented data from its FALCON natural history study, which enrolled 47 patients across 10 sites in the United States, United Kingdom, Italy and Denmark. Results showed patients with ADOA experience higher levels of mitochondrial oxidative stress compared with healthy individuals.
STK-002 has received orphan drug designation from the FDA. Eight clinical trial sites are now active across the UK, Germany, Denmark, Italy and Austria.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Stoke Therapeutics presents data on ADOA treatment STK-002
View all comments (0)
0
Latest comments
Post
Comment Guidelines
Trade With A Regulated Broker
Indices
Commodities
Bonds
Stocks
US 30
51,749.50
+94.3
+0.18%
US 500
7,817.50
+6.0
+0.08%
Dow Jones
51,654.95
+423.31
+0.83%
S&P 500
7,811.54
+46.18
+0.59%
Nasdaq
27,366.17
+172.83
+0.64%
S&P 500 VIX
15.44
+0.60
+4.04%
Dollar Index
102.188
+0.166
+0.16%
Crude Oil WTI Futures
93.24
+1.39
+1.51%
Brent Oil Futures
106.00
+1.28
+1.22%
Natural Gas Futures
3.137
-0.083
-2.58%
Gold Futures
4,195.82
-20.48
-0.49%
Silver Futures
60.965
-0.083
-0.14%
Copper Futures
6.7733
+0.0813
+1.21%
US Soybeans Futures
1,285.75
-5.25
-0.41%
U.S. 10Y
5.254
+0.010
+0.19%
U.S. 30Y
5.599
-0.008
-0.14%
U.S. 5Y
5.021
+0.030
+0.60%
U.S. 3M
4.159
+0.008
+0.19%
US 10Y T-Note Futures
104.52
-0.08
-0.07%
Euro Bund Futures
121.08
0.00
0.00%
10-2 Yield Spread
31.32
+4.15
+15.27%
AAPL
336.64
-3.78
-1.11%
NVDA
229.28
-1.20
-0.52%
GOOGL
351.66
+3.37
+0.97%
TSLA
382.70
+7.70
+2.05%
AMZN
262.43
+8.37
+3.29%
NFLX
70.30
-1.27
-1.77%
META
718.67
-2.22
-0.31%
Advertisement
Most Popular Articles
News
Analysis
Goldman names 3 names to benefit as high-performance NAND tackles AI’s memory wall
By Investing.co
...
Oct 12, 2026
Oil falls, CPI and bank earnings in focus - what’s moving markets
By Investing.co
...
Oct 12, 2026
What the sell off in bonds means for monetary policy
By Investing.co
...
Oct 11, 2026
Oil prices rise as attacks on Saudi Arabia overshadow Trump’s Russian supply announcements
By Reuters
Oct 12, 2026
Raymond James upgrades T-Mobile, says SpaceX competition fears are overblown
By Investing.co
...
Oct 12, 2026
Sequence of Return Risk: The Math That Breaks Retirements
By Lance Robert
...
Oct 10, 2026
Beyond Chips: The 3 Layers of the AI Value Chain
By Ivana Delevs
...
Oct 10, 2026
OpenAI’s $20B Revenue Gap: Warning Signs for US Stocks?
By Lee Yang
Oct 09, 2026
Treasury Auctions Explained: Why Bond Auctions Matter Even If You Dont Trade Bonds
By Matthew Well
...
Oct 10, 2026
Wall Street’s Busy Week: Bank Results, CPI and Retail Sales in Focus
By Ali Merchant
Oct 12, 2026
More News
Market Movers
Most Active
Gainers %
Losers %
Name
Last
Chg. %
Vol.
MU
1,029.00
-0.66%
19.92M
NVDA
229.28
-0.52%
84.65M
SPCX
162.57
+1.25%
93.04M
TSLA
382.70
+2.05%
38.95M
AAPL
336.64
-1.11%
37.88M
MSFT
535.07
+2.38%
18.50M
AMZN
262.43
+3.29%
34.77M
Name
Last
Chg. %
Vol.
CCI
79.64
+15.60%
14.39M
MRNA
225.00
+14.21%
28.95M
HUM
431.87
+11.56%
4.99M
AMT
182.24
+9.30%
8.51M
SBAC
182.49
+7.34%
2.36M
DDOG
293.26
+7.11%
3.71M
AKAM
106.95
+6.00%
5.80M
Name
Last
Chg. %
Vol.
TMUS
148.58
-13.27%
19.03M
T
22.18
-10.82%
150.53M
VZ
41.65
-10.14%
95.17M
HPQ
30.20
-6.91%
16.70M
FMC
8.35
-6.39%
5.19M
CHTR
103.38
-5.74%
5.11M
FICO
667.58
-5.63%
1.09M
Advertisement
Trending Stocks
Name
Last
Chg. %
Vol.
MU
1,029.00
-0.66%
19.92M
NVDA
229.28
-0.52%
84.65M
SPCX
162.57
+1.25%
93.04M
PLTR
209.05
+5.17%
37.62M
IREN
35.190
-1.46%
38.53M
Show more
Advertisement
ProPicks AI
AI-powered
stock picks
with a proven track record to
beat the S&P 500
.
Tech Titans
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Top Value Stocks
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Best of Buffett
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Energy Elite
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Financial Fortresses
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Quality Compounders
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Small-Cap Sprinters
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Healthcare Heroes
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Beat the S&P 500
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Dominate the Dow
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Mid-Cap Movers
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Mexican Stock Exchange Leaders
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Best Brazilian Stocks
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Italian Market Elite
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Alpha Germany Select
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Comments
Post
Comment Guidelines
Tools
Calendars
Economic Calendar
Earnings Calendar
Holiday Calendar
US Economy
Fed Rate Monitor Tool
US Treasury Yield Curve
More Tools
Stock Screener
Currency Converter
Markets
Ask WarrenAI
Stocks Picked by AI
Watchlist
Alerts
Top Brokers
Breaking News
Tools
Install Our App
Scan QR code to install app
Follow us
Advertisement
Advertisement
Stoke Therapeutics presents data on ADOA treatment STK-002
Company News
Published
Oct 12, 2026, 08:04 AM
Stoke Therapeutics presents data on ADOA treatment STK-002
View all comments (0)
0
Stoke Therapeutics presents data on ADOA treatment STK-002
View all comments (0)
0
© Reuters
In this article:
STOK
+
3.30%
BEDFORD, Mass. -
Stoke Therapeutics
Inc. (
NASDAQ:STOK
) presented data on its experimental treatment STK-002 for Autosomal Dominant Optic Atrophy at the American Academy of Ophthalmology 2026 Annual Meeting, which concluded Sunday in New Orleans.
The company announced that dosing has been completed in the first two cohorts of its Phase 1 OSPREY study, with the third cohort expected to complete by the end of 2026. Initial safety and efficacy data from cohorts three and four are anticipated in the first half of 2027, according to a press release statement.
ADOA is the most common inherited optic nerve disorder, affecting approximately one in 25,000 people globally. The condition is primarily caused by variants in the OPA1 gene, resulting in insufficient levels of OPA1 protein and leading to progressive vision loss. There are currently no approved treatments for the disease.
STK-002 is an antisense oligonucleotide designed to increase functional OPA1 protein by targeting the healthy copy of the OPA1 gene. An estimated 65% to 90% of ADOA cases are caused by variants in the OPA1 gene.
The OSPREY study is enrolling children and adults ages 6 to 55 with confirmed ADOA diagnoses and disease-causing OPA1 gene variants. The study’s primary objectives are to assess safety and tolerability of single ascending doses of STK-002, with secondary objectives evaluating changes in visual function and quality of life.
"Dose cohorts three and four are designed to show measurable effects on visual function," said Barry Ticho, Chief Medical Officer of Stoke Therapeutics.
The company also presented data from its FALCON natural history study, which enrolled 47 patients across 10 sites in the United States, United Kingdom, Italy and Denmark. Results showed patients with ADOA experience higher levels of mitochondrial oxidative stress compared with healthy individuals.
STK-002 has received orphan drug designation from the FDA. Eight clinical trial sites are now active across the UK, Germany, Denmark, Italy and Austria.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Stoke Therapeutics presents data on ADOA treatment STK-002
View all comments (0)
0
Latest comments
Post
Comment Guidelines
Trade With A Regulated Broker
Indices
Commodities
Bonds
Stocks
US 30
51,749.50
+94.3
+0.18%
US 500
7,817.50
+6.0
+0.08%
Dow Jones
51,654.95
+423.31
+0.83%
S&P 500
7,811.54
+46.18
+0.59%
Nasdaq
27,366.17
+172.83
+0.64%
S&P 500 VIX
15.44
+0.60
+4.04%
Dollar Index
102.188
+0.166
+0.16%
Crude Oil WTI Futures
93.24
+1.39
+1.51%
Brent Oil Futures
106.00
+1.28
+1.22%
Natural Gas Futures
3.137
-0.083
-2.58%
Gold Futures
4,195.82
-20.48
-0.49%
Silver Futures
60.965
-0.083
-0.14%
Copper Futures
6.7733
+0.0813
+1.21%
US Soybeans Futures
1,285.75
-5.25
-0.41%
U.S. 10Y
5.254
+0.010
+0.19%
U.S. 30Y
5.599
-0.008
-0.14%
U.S. 5Y
5.021
+0.030
+0.60%
U.S. 3M
4.159
+0.008
+0.19%
US 10Y T-Note Futures
104.52
-0.08
-0.07%
Euro Bund Futures
121.08
0.00
0.00%
10-2 Yield Spread
31.32
+4.15
+15.27%
AAPL
336.64
-3.78
-1.11%
NVDA
229.28
-1.20
-0.52%
GOOGL
351.66
+3.37
+0.97%
TSLA
382.70
+7.70
+2.05%
AMZN
262.43
+8.37
+3.29%
NFLX
70.30
-1.27
-1.77%
META
718.67
-2.22
-0.31%
Advertisement
Most Popular Articles
News
Analysis
Goldman names 3 names to benefit as high-performance NAND tackles AI’s memory wall
By Investing.co
...
Oct 12, 2026
Oil falls, CPI and bank earnings in focus - what’s moving markets
By Investing.co
...
Oct 12, 2026
What the sell off in bonds means for monetary policy
By Investing.co
...
Oct 11, 2026
Oil prices rise as attacks on Saudi Arabia overshadow Trump’s Russian supply announcements
By Reuters
Oct 12, 2026
Raymond James upgrades T-Mobile, says SpaceX competition fears are overblown
By Investing.co
...
Oct 12, 2026
Sequence of Return Risk: The Math That Breaks Retirements
By Lance Robert
...
Oct 10, 2026
Beyond Chips: The 3 Layers of the AI Value Chain
By Ivana Delevs
...
Oct 10, 2026
OpenAI’s $20B Revenue Gap: Warning Signs for US Stocks?
By Lee Yang
Oct 09, 2026
Treasury Auctions Explained: Why Bond Auctions Matter Even If You Dont Trade Bonds
By Matthew Well
...
Oct 10, 2026
Wall Street’s Busy Week: Bank Results, CPI and Retail Sales in Focus
By Ali Merchant
Oct 12, 2026
More News
Market Movers
Most Active
Gainers %
Losers %
Name
Last
Chg. %
Vol.
MU
1,029.00
-0.66%
19.92M
NVDA
229.28
-0.52%
84.65M
SPCX
162.57
+1.25%
93.04M
TSLA
382.70
+2.05%
38.95M
AAPL
336.64
-1.11%
37.88M
MSFT
535.07
+2.38%
18.50M
AMZN
262.43
+3.29%
34.77M
Name
Last
Chg. %
Vol.
CCI
79.64
+15.60%
14.39M
MRNA
225.00
+14.21%
28.95M
HUM
431.87
+11.56%
4.99M
AMT
182.24
+9.30%
8.51M
SBAC
182.49
+7.34%
2.36M
DDOG
293.26
+7.11%
3.71M
AKAM
106.95
+6.00%
5.80M
Name
Last
Chg. %
Vol.
TMUS
148.58
-13.27%
19.03M
T
22.18
-10.82%
150.53M
VZ
41.65
-10.14%
95.17M
HPQ
30.20
-6.91%
16.70M
FMC
8.35
-6.39%
5.19M
CHTR
103.38
-5.74%
5.11M
FICO
667.58
-5.63%
1.09M
Advertisement
Trending Stocks
Name
Last
Chg. %
Vol.
MU
1,029.00
-0.66%
19.92M
NVDA
229.28
-0.52%
84.65M
SPCX
162.57
+1.25%
93.04M
PLTR
209.05
+5.17%
37.62M
IREN
35.190
-1.46%
38.53M
Show more
Advertisement
ProPicks AI
AI-powered
stock picks
with a proven track record to
beat the S&P 500
.
Tech Titans
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Top Value Stocks
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Best of Buffett
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Energy Elite
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Financial Fortresses
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Quality Compounders
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Small-Cap Sprinters
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Healthcare Heroes
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Beat the S&P 500
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Dominate the Dow
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Mid-Cap Movers
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Mexican Stock Exchange Leaders
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Best Brazilian Stocks
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Italian Market Elite
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Alpha Germany Select
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Comments
Post
Comment Guidelines
Tools
Calendars
Economic Calendar
Earnings Calendar
Holiday Calendar
US Economy
Fed Rate Monitor Tool
US Treasury Yield Curve
More Tools
Stock Screener
Currency Converter
Markets
Ask WarrenAI
Stocks Picked by AI
Watchlist
Alerts
Top Brokers
Breaking News
Tools
Install Our App
Scan QR code to install app
Follow us
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
b3912055b2· 2026-10-12 20:07 · doubao / doubao-seed-evolving-latest-version · 策略包2226518bfdee当前